China Spinal Muscular Atrophy (SMA) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 11.7% during the forecast period.
Spinal muscular atrophy (SMA) is a group of inherited disorders characterized by a loss of certain nerve cells in the spinal cord called motor neurons or anterior horn cells. The loss of motor neurons leads to progressive muscle weakness and muscle wasting (atrophy) in muscles closest to the trunk of the body (proximal muscles) such as the shoulders, hips and back. SMA affects between 1 in 6,000 and 1 in 10,000 in China, and about 95 percent of the patients die 18 months after birth. SMA type 1 is the most common type of SMA and is also a severe form of the disease.
China is a growing market for spinal muscular atrophy (SMA) due to factors such as increase in China’s incidence rate (1 in 6,000 and 1 in 10,000). In addition to this, other factors that contribute to the growth of market are rise in healthcare expenditure, increase in awareness and availability of novel therapeutics and unmet needs of patients.
However, there are some restraining factors for growth of spinal muscular atrophy (SMA) therapeutics market in China such high cost of treatment for spinal muscular atrophy (SMA) and lack of experienced professionals.